Its retrospective design precluded capture of critical data, such as CD4 counts in HIV-related KS or detailed immunosuppressive regimen adjustments in iKS, limiting subgroup analyses and the assessment of quality-of-life (QoL). Here, CD4 is linked to Kaposi's sarcoma.